The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation
Open accessAbstract
OBJECTIVES: Linaclotide is a minimally absorbed guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C). METHODS: This phase 3, double-blind, parallel-group, placebo-controlled trial randomized IBS-C patients to placebo or 290 μ g oral linaclotide once daily in a 12-week treatment period, followed by a 4-week randomized withdrawal (RW) period. There were four primary end points, the Food and Drug Administration ’ s (FDA ’ s) primary end point for IBS-C (responder: improvement of ≥ 30 % in average daily worst abdominal pain score and increase by ≥ 1 complete spontaneous bowel movement (CSBM) from baseline (same week) for at least 50 % of weeks assessed) and three other primary end points, based on improvements in abdominal pain and CSBMs for 9 / 12 weeks. Adverse events (AEs) were monitored. RESULTS: The trial evaluated 800 patients (mean age = 43.5 years, female = 90.5 % , white = 76.9 % ). The FDA end point was met by 136 / 405 linaclotide-treated patients (33.6 % ), compared with 83 / 395 placebo-treated patients (21.0 % ) ( P < 0.0001) (number needed to treat: 8.0, 95 % confidence interval: 5.4, 15.5). A greater percentage of linaclotide patients, compared with placebo patients, reported for at least 6 / 12 treatment period weeks, a reduction of ≥ 30 % in abdominal pain (50.1 vs. 37.5 % , P = 0.0003) and an increase of ≥ 1 CSBM from baseline (48.6 vs. 29.6 % , P < 0.0001). A greater percentage of linaclotide patients vs. placebo patients were also responders for the other three primary end points ( P < 0.05). Significantly greater improvements were seen in linaclotide vs. placebo patients for all secondary end points ( P < 0.001). During the RW period, patients remaining on linaclotide showed sustained improvement; patients re-randomized from linaclotide to placebo showed return of symptoms, but without worsening of symptoms relative to baseline. Diarrhea, the most common AE, resulted in discontinuation of 5.7 % of linaclotide and 0.3 % of placebo patients. CONCLUSIONS: Linaclotide significantly improved abdominal pain and bowel symptoms associated with IBS-C for at least 12 weeks; there was no worsening of symptoms compared with baseline following cessation of linaclotide during the RW period.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Farrar, J. T., Young, J. P., LaMoreaux, L., Werth, J. L., & Poole, M. R. (2001) · Pain · doi:10.1016/s0304-3959(01)00349-9 · Cited by 5,808
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Stool form scale as a useful guide to intestinal transit time
Lewis, S. J., & Heaton, K. W. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709011203 · Cited by 3,244
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440
WINAWER, S. (2003) · Gastroenterology · doi:10.1053/gast.2003.50044 · Cited by 2,143
AGA technical review on irritable bowel syndrome.
Drossman, D. A., Camilleri, M., Mayer, E. A., & Whitehead, W. E. (2002) · Gastroenterology · doi:10.1053/gast.2002.37095 · Cited by 1,384
Hungin, A. P. S., Whorwell, P. J., Tack, J., & Mearin, F. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01456.x · Cited by 781
An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
American College of Gastroenterology IBS Task Force (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.122 · Cited by 694
Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact
Hungin, A. P. S., Chang, L., Locke, G. R., Dennis, E. H., & Barghout, V. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02463.x · Cited by 494
DROSSMAN, D. A., CHEY, W. D., JOHANSON, J. F., FASS, R., SCOTT, C., PANAS, R., & UENO, R. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03881.x · Cited by 399
Two randomized trials of linaclotide for chronic constipation
Lembo, A. J., Schneier, H. A., Shiff, S. J., Kurtz, C. B., MacDougall, J. E., Jia, X. D., Shao, J. Z., Lavins, B. J., Currie, M. G., Fitch, D. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010863 · Cited by 373 · cited 1×
“Likewise, in two large phase 3 trials in patients with chronic constipation, linaclotide signifi cantly improved bowel and abdominal symptoms over 12 weeks ( 17 ).”
BackgroundSelf-citationAndresen, V., Camilleri, M., Busciglio, I. A., Grudell, A., Burton, D., McKinzie, S., Foxx–Orenstein, A., Kurtz, C. B., Sharma, V., Johnston, J. M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.06.067 · Cited by 245
Self-citationMayer, E. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0801447 · Cited by 243
Johnston, J. M., Kurtz, C. B., MacDougall, J. E., Lavins, B. J., Currie, M. G., Fitch, D. A., O'Dea, C., Baird, M., & Lembo, A. J. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.08.041 · Cited by 229
Self-citationThe Burden of Illness of Irritable Bowel Syndrome: Current Challenges and Hope for the Future
Hulisz, D. (2004) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2004.10.4.299 · Cited by 215 · cited 1×
“Traditional therapies for IBS-C, generally directed towards the patient ’ s predominant symptoms ( 9 ), are frequently associated with patient dissatisfaction ( 10 ).”
BackgroundBryant, A. P., Busby, R. W., Bartolini, W. P., Cordero, E. A., Hannig, G., Kessler, M. M., Pierce, C. M., Solinga, R. M., Tobin, J. V., Mahajan-Miklos, S., et al. (2010) · Life Sciences · doi:10.1016/j.lfs.2010.03.015 · Cited by 208
Self-citationParé, P., Gray, J., Lam, S., Balshaw, R., Khorasheh, S., Barbeau, M., Kelly, S., & McBurney, C. R. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.10.010 · Cited by 199
eutamene, H., bradesi, S., larauche, M., theodorou, V., beaufrand, C., ohning, G., fioramonti, J., cohen, M., bryant, A. P., kurtz, C., et al. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01385.x · Cited by 188
Self-citationSpiegel, B. M. R., Bolus, R. R., Harris, L. A., Lucak, S. L., Naliboff, B. D., Esrailian, E., Chey, W. D., Lembo, A. J., Karsan, H. A., Tillisch, K., et al. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04144.x · Cited by 118
Self-citationIrritable Bowel Syndrome: Toward an Understanding of Severity
Lembo, A. J., Ameen, V. Z., & Drossman, D. A. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(05)00157-6 · Cited by 103
Self-citationTotal costs of IBS: employer and managed care perspective.
Cash, B. D., Sullivan, S. D., & Barghout, V. E. (2005) · PubMed · Cited by 87
Hellström, P. M., Saito, Y. A., Bytzer, P. M., Tack, J. F., Mueller‐Lissner, S., & Chang, L. (2011) · The American Journal of Gastroenterology · doi:10.1038/ajg.2011.78 · Cited by 31
A Novel Role of Cyclic GMP in Colonic Sensory Neurotransmission in Healthy and TNBS-Treated Mice
Castro, J., Martin, C., Hughes, P. A., Silos-Santiago, A., Kurtz, C. B., Blackshaw, L. A., & Brierley, S. M. (2011) · Gastroenterology · doi:10.1016/s0016-5085(11)62229-4 · Cited by 19
Self-citation
Cited by
Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.031 · Cited by 2,866
Self-citationEnck, P., Aziz, Q., Barbara, G., Farmer, A. D., Fukudo, S., Mayer, E. A., Niesler, B., Quigley, E. M. M., Rajilić-Stojanović, M., Schemann, M., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.14 · Cited by 997
ACG Clinical Guideline: Management of Irritable Bowel Syndrome
Lacy, B. E., Pimentel, M., Brenner, D. M., Chey, W. D., Keefer, L. A., Long, M. D., & Moshiree, B. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001036 · Cited by 893
Mechanisms, evaluation, and management of chronic constipation
Bharucha, A. E., & Lacy, B. E. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.034 · Cited by 655
Ford, A. C., Moayyedi, P., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Quigley, E. M. M. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.187 · Cited by 645
Self-citation
Metadata
- Authors
- Rao, S., Lembo, A. J., Shiff, S. J., Lavins, B. J., Currie, M. G., Jia, X. D., Shi, K., MacDougall, J. E., Shao, J. Z., Eng, P., Fox, S. M., Schneier, H. A., Kurtz, C. B., & Johnston, J. M.
- Venue
- American Journal of Gastroenterology
- Published
- 2012-11
- Volume
- 107
- Issue
- 11
- Pages
- 1714-1724
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W1997800332
- Cited by
- 384
- References
- 23
- FWCI
- 33.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.